MMRF Statement on FDA Approval of TECVAYLI™, the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Norwalk, CT, Oct. 25, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody. TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment. 

To read Janssen’s full press release click here.

###

Multiple Myeloma Research Foundation Media Contact:

C.J. Volpe, Director, PR and Communications
203.652.0453
volpec@themmrf.org